Holen Sie sich die Stockscreener-App
0.9604
4.91%
-0.0496
Vorhandelsmarkt:
.99
0.0296
+3.08%
Schlusskurs vom Vortag:
$1.01
Offen:
$0.999
24-Stunden-Volumen:
970.83K
Relative Volume:
0.69
Marktkapitalisierung:
$183.39M
Einnahmen:
$4.71M
Nettoeinkommen (Verlust:
$-58.01M
KGV:
-1.1664
EPS:
-0.8234
Netto-Cashflow:
$-46.68M
1W Leistung:
-0.47%
1M Leistung:
-0.92%
6M Leistung:
-29.38%
1J Leistung:
-6.76%
1-Tages-Spanne:
$0.958
$1.01
1-Wochen-Bereich:
$0.958
$1.03
52-Wochen-Spanne:
$0.8605
$1.6293
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Firmenname
Lucid Diagnostics Inc
Sektor
Branche
Telefon
212 949 4319
Adresse
360 MADISON AVENUE, NEW YORK
Compare LUCD vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
0.9604 | 192.86M | 4.71M | -58.01M | -46.68M | -0.8234 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Eingeleitet | BTIG Research | Buy |
| 2021-11-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Needham | Buy |
Lucid Diagnostics Inc Aktie (LUCD) Neueste Nachrichten
Lucid Diagnostics (LUCD) Q2 2026 Earnings Call Transcript - AOL.com
Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says - Sahm
PAVmed Q2 2026 slides: loss narrows as device programs advance By Investing.com - Investing.com Nigeria
PAVmed Q2 2026 slides: loss narrows as cash position weakens By Investing.com - Investing.com Nigeria
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth - MarketBeat
PAVmed Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
Lucid Diagnostics (LUCD) Rises 1.97% as Shares Hold Above Critical Support at $0.93SMA Signal - dars.gov.et
PAVmed Q2 2026 slides: loss narrows as cash position weakens - Investing.com
PAVmed Q2 Results: Revenue jumps to $33k, cash rises to $3.8m - scanx.trade
Earnings call transcript: PAVmed narrows Q2 2026 loss as shares slip - Investing.com South Africa
PAVmed Q2 2026 slides: loss narrows as device programs advance - Investing.com
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Lucid Diagnostics (LUCD) Earnings Call zu Q2 2026: Umsatz steigt um 17 %, Concert-Kostendeckung macht Fortschritte - TradingKey
Lucid Diagnostics earnings matched, revenue topped estimates By Investing.com - Investing.com Canada
Lucid Diagnostics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LUCD) 2026-08-13 - Seeking Alpha
Lucid Diagnostics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
LUCD Looks 16.3% Overvalued on GF Value™ - GuruFocus
Lucid Diagnostics (LUCD) Slips 1.98% to $0.96 as Shares Hover Above Key SupportRunaway Gap - dars.gov.et
Financial Report LiveLucid Diagnostics Inc. (LUCD.US) Q2 2026 Earnings Conference Call - Longbridge
Lucid Diagnostics Q2 Earnings Call Highlights - MarketBeat
Needham reiterates Buy on Lucid Diagnostics stock, $3 target By Investing.com - Investing.com South Africa
Needham reiterates Buy on Lucid Diagnostics stock, $3 target - Investing.com
Lucid Diagnostics Q2 2026 revenue up 17% QoQ; secures first LBM coverage - scanx.trade
Lucid Diagnostics Q2 2026 Earnings Call: Complete Transcript - Benzinga
LUCD: Revenue up 17% with stable cash, first LBM coverage, and Medicare LCD decision expected soon - TradingView
Transcript : Lucid Diagnostics Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip - Investing.com
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Form 8K Lucid Diagnostics Inc For: 13 August By Investing.com - Investing.com South Africa
PAVmed subsidiary Lucid Diagnostics posts 2Q revenue of USD 1.5 million - Bitget
Lucid Diagnostics Reports Q2 Growth Ahead of Medicare Decision - TipRanks
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
Lucid Diagnostics Q2 2026 Earnings Call Transcript - MarketBeat
Lucid Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue - Quiver Quantitative
Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary - TradingView
Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load - Stock Titan
Lucid Diagnostics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside - Yahoo Finance
Lucid Diagnostics Q2 FY26 revenue rises 25% to USD 1.5 million - Bitget
Lucid Diagnostics at canaccord growth conference: reimbursement push builds By Investing.com - Investing.com Australia
Lucid Diagnostics Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Enterprise value to EBIT forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - tradingview.com
Price to sales forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to book forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Price to earnings forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - TradingView
Enterprise value to EBITDA forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - tradingview.com
Enterprise value to revenue forward of Lucid Diagnostics Inc. – NASDAQ:LUCD - tradingview.com
Finanzdaten der Lucid Diagnostics Inc-Aktie (LUCD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):